Scarica l'app Stockscreener
36.13
1.87%
-0.69
Pre-mercato:
36.26
0.13
+0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$36.82
Aprire:
$36.64
Volume 24 ore:
5.66M
Relative Volume:
0.79
Capitalizzazione di mercato:
$26.10B
Reddito:
$8.26M
Utile/perdita netta:
$-397.91M
Rapporto P/E:
-71.74
EPS:
-0.5036
Flusso di cassa netto:
$-758.56M
1 W Prestazione:
-9.63%
1M Prestazione:
-0.63%
6M Prestazione:
+34.46%
1 anno Prestazione:
+145.78%
Intervallo 1D:
$35.91
$36.75
Intervallo di 1 settimana:
$35.91
$40.71
Portata 52W:
$14.59
$42.50
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
36.13 | 26.10B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Outperform |
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging? - Insider Monkey
Cantor Fitzgerald reiterates Roivant Sciences stock rating By Investing.com - Investing.com Canada
Roivant Sciences Ltd. (ROIV) Stock Forecasts - finance.yahoo.com
ROIV Looks 361.0% Overvalued on GF Value™ - GuruFocus
Roivant Sciences Ltd. (ROIV) stock price, news, quote and history - Yahoo Finance UK
Why Is Immunovant Stock Falling Wednesday?Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT) - Benzinga
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss - Yahoo Finance
Roivant slips on trial setback for Immunovant (ROIV:NASDAQ) - Seeking Alpha
A skin-lupus drug study missed its main goal. Its developer plans to stop testing it. - Stock Titan
Behavioral Patterns of ROIV and Institutional Flows - Stock Traders Daily
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History - ca.finance.yahoo.com
Roivant (ROIV) CAO uses 3,880 shares to cover RSU taxes - Stock Titan
Form 4 Roivant Sciences Ltd. For: 22 September By Investing.com - Investing.com Australia
Roivant Sciences (ROIV) CFO now holds 269,681 shares after RSU tax withholding - Stock Titan
Why Roivant Sciences (ROIV) Is Back In The Spotlight - simplywall.st
Transcript : Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2026, Sep-22-2026 12 - marketscreener.com
Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test - finance.yahoo.com
Roivant Sciences Ltd. (ROIV) Stock Analysis: Analyzing a 20% Potential Upside Amid Biotech Innovation - DirectorsTalk Interviews
Did Positive PH ILD Trial Data Just Shift Roivant Stock Investment Narrative? - simplywall.st
Roivant Sciences (ROIV) director receives new 2027-vesting equity grant - Stock Titan
Roivant Sciences (ROIV) director now holds 8.97M shares - Stock Titan
New stock awards for Roivant Sciences (ROIV) director vest in 2027 - Stock Titan
Roivant Sciences (ROIV) grants director stock awards vesting in 2027 - Stock Titan
Roivant Sciences (ROIV) gives director new options and RSUs - Stock Titan
Director at Roivant (ROIV) receives new stock awards - Stock Titan
What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data? - finance.yahoo.com
Director Melissa Epperly Sells 4,938 Shares of Roivant Sciences Ltd (ROIV) - GuruFocus
Roivant Sciences (NASDAQ: ROIV) director sells 4,938 shares under 10b5-1 plan - Stock Titan
Roivant Sciences (ROIV) director sells 5,112 shares under pre-set plan - Stock Titan
ROIV Initiates Coverage by Stifel -- Price Target Announced at $51 - GuruFocus
Roivant Sciences Initiated at Buy by Stifel - Moomoo
Stifel initiates Roivant Sciences stock with buy rating, $51 target By Investing.com - Investing.com South Africa
Stifel initiates Roivant Sciences stock with buy rating, $51 target - Investing.com
Roivant Sciences (ROIV) director lines up $930K stock sale - Stock Titan
Roivant Sciences (NASDAQ: ROIV) officer to sell 5,112 shares - Stock Titan
Why Roivant Sciences (ROIV) Stock Is Down Today - quiverquant.com
Roivant Sciences Director Melissa B. Epperly Forfeits 2,179 Shares at $40.94 Each (NASDAQ: ROIV) - Kalkine Media
Roivant Sciences (ROIV) director uses shares to cover tax bill - Stock Titan
Roivant Sciences (ROIV) director uses stock to cover tax bill - Stock Titan
Roivant Sciences Ltd. (ROIV) Stock Analysis: High Analyst Confidence with a 12.58% Upside Potential - DirectorsTalk Interviews
Roivant Sciences (ROIV) director uses shares to cover taxes - Stock Titan
ROIV gains commercial footing with LISRAYA appr... - Pluang
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story - Yahoo Finance
(ROIV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Roivant Sciences (ROIV) Could Be 308% Overvalued Following Phase 2 Mosliciguat Data - simplywall.st
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Roivant Sciences (ROIV) director sells stock under preset plan - Stock Titan
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILDSlideshow (NASDAQ:ROIV) 2026-09-10 - Seeking Alpha
ROIV: FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook - TradingView
Did Phase 2 Trial Win Just Shift Roivant Sciences (ROIV) Investment Narrative? - simplywall.st
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
1.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):